Dr. Salloway is an internationally recognized leader in clinical trials for the prevention and treatment of Alzheimer’s disease. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. He is the founding Director of the Memory and Aging Program (MAP) at Butler Hospital, Associate Director of the Brown Center for Alzheimer’s Disease Research, a Professor of Neurology, and Professor, Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University. His program has conducted more than 125 clinical trials for Alzheimer’s and related disorders. He has chaired the Steering Committees for major AD pivotal trials, such as bapineuzumab and aducanumab, and he has been a lead author for key publications in Alzheimer’s research. He is also a founding member on the steering committees for major biomarker and clinical trials and consortia such as ADNI, DIAN, ACTC, and LEADS. He has published more than 400 scientific articles and abstracts and edited 3 books and he lectures widely about the early diagnosis and prevention of Alzheimer’s disease. He is an expert on amyloid-related imaging abnormalities and its management and is a member of the Alzheimer’s Disease and Related Disorders Therapeutic Work Group developing appropriate use recommendations to safely guide the clinical use of new disease-modifying treatments. He is the Principal Investigator for the New England site of the landmark US POINTER lifestyle intervention trial and his team recently launched a new cohort, the Biofinder: Brown study, in collaboration with Oskar Hansson’s group in Lund, Sweden, to validate plasma biomarkers in preclinical Alzheimer’s disease.

Gemma Salvadó, PhD, is currently a post-doctoral researcher in Dr. Oskar Hansson's group at Lund University (Sweden). Gemma completed her PhD at the Barcelonaβeta Brain Research Center (Spain), where she focused on understanding the preclinical stages of Alzheimer's disease through the use of neuroimaging and fluid biomarkers. Her current work involves studying plasma and cerebrospinal fluid biomarkers to gain insights into the disease progression. She is currently a Marie Skłodowska-Curie post-doctoral awardee among other important grants.

As a director of research at INSERM (the French National Institute for Health), Cécilia Samieri leads a group on the “exposome of brain aging and dementia” in the Bordeaux Population Health research center. She studies the epidemiology of brain aging, with the aim of understanding how the environment influences the etiology of dementia, developing original approaches to address lifestyle and brain health with a holistic vision, from diet patterns to molecular markers of the exposome. Trained as a veterinary and then as a neuro-epidemiologist in Bordeaux and as a Fulbright post-doctoral fellow at Harvard School of Public health in Boston, she leveraged large French and US cohorts to evidence associations of healthy diets and optimal cardiovascular health, with healthy brain aging. She served as academic co-chair of the Alzheimer’s Association's Professional Interest Area group on Nutrition and Metabolic Diseases from 2019 to 2021. In 2022 she has set up a new population-based cohort of your seniors after age 55 as a unique tool to evaluate, with high-throughput molecular and imaging-based epidemiology, the exposome and early signs of neuropathology. The overarching goal is to inform next-generation public health policies, integrating behaviors with contextual factors for the precision prevention of cognitive aging.

Dr. Sanchez completed his PhD in Neuroscience at University of Montréal in 2022. His doctoral research, performed at the Center for Advanced Research in Sleep Medicine with Dr. Nadia Gosselin, aimed to study sleep and neuroimaging markers in patients with acute and chronic traumatic brain injuries to achieve better recovery and prognosis. Dr. Sanchez is currently a postdoctoral research fellow at the Sunnybrook Research Institute, working with Dr. Mario Masellis. His current research aims to understand the predictive value of plasma biomarkers for cognitive and neuroimaging markers in patients diagnosed with neurodegenerative diseases.